LAS41005

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Apr 1, 2011 → Aug 1, 2012

NCT ID

NCT01358851

About LAS41005

LAS41005 is a phase 2 stage product being developed by Almirall for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01358851. Target conditions include Actinic Keratosis.

What happened to similar drugs?

6 of 20 similar drugs in Actinic Keratosis were approved

Approved (6) Terminated (1) Active (14)

🔄Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3

🔄KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3

✅fluorouracil cream 0.5%SanofiApproved

✅Imiquimod + DiclofenacViatrisApproved

🔄Aldara (Imiquimod)ViatrisPhase 3

✅Imiquimod + DiclofenacViatrisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01358851	Phase 2	Completed	Apr 1, 2011	Aug 1, 2012	Actinic Keratosis

Competing Products

20 competing products in Actinic Keratosis

See all competitors

Product	Company	Stage	Hype Score
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice daily	Dr. Reddy's Laboratories	Phase 2/3	35
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	44
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%	Sun Pharmaceutical	Phase 3	44
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical Gel	Sun Pharmaceutical	Phase 1	29
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical Cream	Sun Pharmaceutical	Phase 1	29
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by Taro	Sun Pharmaceutical	Phase 1	29
Investigational Treatment + Active comparator	Novartis	Phase 2	35
KX01 ointment 1% + Placebo	PharmaEssentia	Phase 3	40
Fluorouracil	Sanofi	Phase 1/2	32
fluorouracil cream 0.5%	Sanofi	Approved	43
Imiquimod + Diclofenac	Viatris	Approved	40
Imiquimod 5 % Cream	Viatris	Phase 2	32
Imiquimod	Viatris	Pre-clinical	23
Aldara (Imiquimod)	Viatris	Phase 3	37
Imiquimod + Diclofenac	Viatris	Approved	40
Placebo Gel + LAS41005 + LAS106521	Almirall	Phase 3	34
5-fluorouracil/salicylic acid + Vehicle	Almirall	Phase 3	34
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%	Almirall	Phase 2	29
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% Gel	Almirall	Approved	41
KX2-391 Ointment 1% + Placebo	Almirall	Phase 3	34